Disease Info Card

Embryonal Carcinoma

Information about Embryonal Carcinoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Embryonal Carcinoma

Most recent studies have shown that Embryonal Carcinoma shares some biological mechanisms with brain-neoplasms, carcinoma, cell-transformation-neoplastic, choriocarcinoma, dysgerminoma, germ-cell-tumor, germinoma, immature-teratoma, malignant-neoplasm-of-testis, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasm-metastasis, neoplasms, neoplasms-germ-cell-and-embryonal, ovarian-neoplasm, seminoma, teratocarcinoma, teratoma, testicular-neoplasms, yolk-sac-tumor.

Among the many pathways, these few ones have gauged particular interests from scientists studying Embryonal Carcinoma, and have been seen in publications frequently: Cell Adhesion, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Demethylation, Dna Methylation, Dna Replication, Glycosylation, Localization, Methylation, Neurogenesis, Pathogenesis, Response To Retinoic Acid, Rna Interference, Secretion, Spermatogenesis, Stem Cell Differentiation, Translation

Quite a number of genes have been found to play important roles in Embryonal Carcinoma, such as AFP, BBS9, CDKN2A, CDKN2D, EGF, F9, FGF4, FOS, FUT4, IL23A, JUN, LIF, LMOD1, POU5F1, RARA, REG1A, TNFRSF8, TP53, TRIM26. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.